T0	Limitation 15905 15906	A
T1	Limitation 16075 16082	Because
T2	Limitation 16271 16278	Delayed
T3	Limitation 16431 16434	For
T4	Limitation 16595 16607	Furthermore,
T5	Limitation 16681 16683	We
T6	Limitation 16812 16814	We
T7	Limitation 17068 17070	An
T8	Limitation 17235 17237	We
T9	Limitation 18071 18073	In
T10	LackOfOutcomeMeasurementData 15987 16073	did not call patients back for study visits for detailed assessment of quality of life
T11	LackOfOutcomeMeasurementData 16359 16429	we did not include delayed cerebral haemorrhage as a secondary outcome
#1	AnnotatorNotes T1	Incorrect
T12	LackOfOutcomeMeasurementData 16452 16593	we did not include other baseline measurements such as amount of blood in CT scan or systemic illness, nor did we do close on-site monitoring
#2	AnnotatorNotes T12	This about more than only outcome measurements, but this item is closest to what the issue is
T13	LackOfOutcomeMeasurementData 16608 16679	we do not have complete information about adherence to study medication
#3	AnnotatorNotes T13	An issue of treatment (between-group) contrast, like in a previous study I scored, reflecting on this, one might see this as an issue of a missing outcome measure
T14	LackOfOutcomeMeasurementData 16681 16747	We did not require magnesium concentration to be routinely checked
T15	CareProvider 16830 16875	the possibility of unmasking of investigators
T16	ReliabilityOfMeasurement 17071 17204	effect of magnesium treatment on cognitive symptoms—which are common after aneurysmal subarachnoid haemorrhage—might have been missed
T17	InappropriateFollowUpDuration 17371 17404	a benefit might be detected later
T18	Limitation 18088 18163	time to treatment with magnesium in MASH 2 might not have been short enough
#4	AnnotatorNotes T18	TREATMENT INITIATION TOO LATE
